Machine learning-based prediction of surgical benefit in borderline resectable and locally advanced pancreatic cancer

被引:0
|
作者
Zhang, Leiming [1 ,2 ]
Yu, Zehao [2 ]
Jin, Rong [1 ,2 ]
Yang, Xuanang [2 ]
Ying, Dongjian [1 ]
机构
[1] Ningbo Univ, Affiliated Lihuili Hosp, Dept Minimally Invas Surg, Ningbo, Zhejiang, Peoples R China
[2] Ningbo Univ, Hlth Sci Ctr, Ningbo, Zhejiang, Peoples R China
关键词
Machine learning; Borderline resectable pancreatic cancer; Locally advanced pancreatic cancer; Postoperative; Model prediction; DUCTAL ADENOCARCINOMA; SURGERY; 5-FLUOROURACIL; CHEMOTHERAPY; FOLFIRINOX; CONSENSUS; THERAPY;
D O I
10.1007/s00432-023-05071-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
IntroductionSurgery represents a primary therapeutic approach for borderline resectable and locally advanced pancreatic cancer (BR/LAPC). However, BR/LAPC lesions exhibit high heterogeneity and not all BR/LAPC patients who undergo surgery can derive beneficial outcomes. The present study aims to employ machine learning (ML) algorithms to identify those who would obtain benefits from the primary tumor surgery.MethodsWe retrieved clinical data of patients with BR/LAPC from the Surveillance, Epidemiology, and End Results (SEER) database and classified them into surgery and non-surgery groups based on primary tumor surgery status. To eliminate confounding factors, propensity score matching (PSM) was employed. We hypothesized that patients who underwent surgery and had a longer median cancer-specific survival (CSS) than those who did not undergo surgery would certainly benefit from surgical intervention. Clinical and pathological features were utilized to construct six ML models, and model effectiveness was compared through measures such as the area under curve (AUC), calibration plots, and decision curve analysis (DCA). We selected the best-performing algorithm (i.e., XGBoost) to predict postoperative benefits. The SHapley Additive exPlanations (SHAP) approach was used to interpret the XGBoost model. Additionally, data from 53 Chinese patients prospectively collected was used for external validation of the model.ResultsAccording to the results of the tenfold cross-validation in the training cohort, the XGBoost model yielded the best performance (AUC = 0.823, 95%CI 0.707-0.938). The internal (74.3% accuracy) and external (84.3% accuracy) validation demonstrated the generalizability of the model. The SHAP analysis provided explanations independent of the model, highlighting important factors related to postoperative survival benefits in BR/LAPC, with age, chemotherapy, and radiation therapy being the top three important factors.ConclusionBy integrating of ML algorithms and clinical data, we have established a highly efficient model to facilitate clinical decision-making and assist clinicians in selecting the population that would benefit from surgery.
引用
收藏
页码:11857 / 11871
页数:15
相关论文
共 50 条
  • [1] Machine learning-based prediction of surgical benefit in borderline resectable and locally advanced pancreatic cancer
    Leiming Zhang
    Zehao Yu
    Rong Jin
    Xuanang Yang
    Dongjian Ying
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 11857 - 11871
  • [2] Resectable, Borderline Resectable, and Locally Advanced Pancreatic Cancer: What Does It Matter?
    Halperin, Daniel M.
    Varadhachary, Gauri R.
    CURRENT ONCOLOGY REPORTS, 2014, 16 (02)
  • [3] Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer
    Ferrone, Cristina R.
    Marchegiani, Giovanni
    Hong, Theodore S.
    Ryan, David P.
    Deshpande, Vikram
    McDonnell, Erin I.
    Sabbatino, Francesco
    Santos, Daniela Dias
    Allen, Jill N.
    Blaszkowsky, Lawrence S.
    Clark, Jeffrey W.
    Faris, Jason E.
    Goyal, Lipika
    Kwak, Eunice L.
    Murphy, Janet E.
    Ting, David T.
    Wo, Jennifer Y.
    Zhu, Andrew X.
    Warshaw, Andrew L.
    Lillemoe, Keith D.
    Fernandez-del Castillo, Carlos
    ANNALS OF SURGERY, 2015, 261 (01) : 12 - 17
  • [4] REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer
    Boggi, Ugo
    Kauffmann, Emanuele
    Napoli, Niccolo
    Barreto, S. George
    Besselink, Marc G.
    Fusai, Giuseppe K.
    Hackert, Thilo
    Abu Hilal, Mohammad
    Marchegiani, Giovanni
    Salvia, Roberto
    Shrikhande, Shailesh V.
    Truty, Mark
    Werner, Jens
    Wolfgang, Christopher L.
    Bannone, Elisa
    Capretti, Giovanni
    Cattelani, Alice
    Coppola, Alessandro
    Cucchetti, Alessandro
    De Sio, Davide
    Di Dato, Armando
    Di Meo, Giovanna
    Fiorillo, Claudio
    Gianfaldoni, Cesare
    Ginesini, Michael
    Salinas, Camila Hidalgo
    Lai, Quirino
    Miccoli, Mario
    Montorsi, Roberto
    Pagnanelli, Michele
    Poli, Andrea
    Ricci, Claudio
    Sucameli, Francesco
    Tamburrino, Domenico
    Viti, Virginia
    Addeo, Pietro F.
    Alfieri, Sergio
    Bachellier, Philippe
    Baiocchi, Gian Luca
    Balzano, Gianpaolo
    Barbarello, Linda
    Brolese, Alberto
    Busquets, Juli
    Butturini, Giovanni
    Caniglia, Fabio
    Caputo, Damiano
    Casadei, Riccardo
    Xi Chunhua
    Colangelo, Ettore
    Coratti, Andrea
    ANNALS OF SURGERY, 2024, 280 (01) : 56 - 65
  • [5] Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
    Alva-Ruiz, Roberto
    Yohanathan, Lavanya
    Yonkus, Jennifer A.
    Abdelrahman, Amro M.
    Gregory, Lindsey A.
    Halfdanarson, Thorvadur R.
    Mahipal, Amit
    McWilliams, Robert R.
    Ma, Wen Wee
    Hallemeier, Christopher L.
    Graham, Rondell P.
    Grotz, Travis E.
    Smoot, Rory L.
    Cleary, Sean P.
    Nagorney, David M.
    Kendrick, Michael L.
    Truty, Mark J.
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (03) : 1579 - 1591
  • [6] Treatment of pancreatic cancer-neoadjuvant treatment in borderline resectable/locally advanced pancreatic cancer
    Scheufele, Florian
    Hartmann, Daniel
    Friess, Helmut
    TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 4
  • [7] Current Surgical Concepts and Future Perspectives in the Treatment of Borderline Resectable and Potentially Resectable Locally Advanced Pancreatic Cancer
    Karamarkovic, Aleksandar R.
    Juloski, Jovan T.
    CHIRURGIA, 2022, 117 (04) : 385 - 398
  • [8] Neoadjuvant Treatment in Locally Advanced and Borderline Resectable Pancreatic Cancer vs Primary Resectable Pancreatic Cancer
    Del Chiaro, Marco
    Valente, Roberto
    Arnelo, Urban
    JAMA SURGERY, 2017, 152 (11) : 1057 - 1057
  • [9] Preoperative treatments in borderline resectable and locally advanced pancreatic cancer: Current evidence and new perspectives
    de Scordilli, Marco
    Michelotti, Anna
    Zara, Diego
    Palmero, Lorenza
    Alberti, Martina
    Noto, Claudia
    Totaro, Fabiana
    Foltran, Luisa
    Guardascione, Michela
    Iacono, Donatella
    Ongaro, Elena
    Fasola, Gianpiero
    Puglisi, Fabio
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2023, 186
  • [10] Pancreatectomy with arterial resection is superior to palliation in patients with borderline resectable or locally advanced pancreatic cancer
    Del Chiaro, Marco
    Rangelova, Elena
    Halimi, Asif
    Ateeb, Zeeshan
    Scandavini, Chiara
    Valente, Roberto
    Segersvard, Ralf
    Arnelo, Urban
    Verbeke, Caroline S.
    HPB, 2019, 21 (02) : 219 - 225